198 related articles for article (PubMed ID: 27684806)
1. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Zhang C; Jing T; Wang F; Gao X; Xu C; Sun Y
Actas Urol Esp; 2014 Apr; 38(3):184-91. PubMed ID: 24507454
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
Qi WX; Shen Z; Yao Y
J Cancer Res Clin Oncol; 2011 Dec; 137(12):1785-90. PubMed ID: 21915752
[TBL] [Abstract][Full Text] [Related]
4. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Song P; Huang C; Wang Y
Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.
Wong YN; Manola J; Hudes GR; Roth BJ; Moul JW; Barsevick AM; Scher RM; Volk MJ; Vaughn DJ; Williams SD; Fisch MJ; Cella D; Carducci MA; Wilding G
Clin Genitourin Cancer; 2018 Apr; 16(2):e315-e322. PubMed ID: 29173976
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer.
Kuramoto T; Inagaki T; Fujii R; Sasaki Y; Nishizawa S; Nanpo Y; Matusmura N; Kohjimoto Y; Hara I
Int J Clin Oncol; 2013 Oct; 18(5):890-7. PubMed ID: 22936562
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 Study of Cyclophosphamide, Etoposide, and Estramustine in Patients With Castration-Resistant Prostate Cancer.
Laber DA; Chen MB; Jaglal M; Patel A; Visweshwar N
Clin Genitourin Cancer; 2018 Dec; 16(6):473-481. PubMed ID: 30072309
[TBL] [Abstract][Full Text] [Related]
10. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
[TBL] [Abstract][Full Text] [Related]
11. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
[TBL] [Abstract][Full Text] [Related]
12. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
Du J; Yang Q; Chen XS; Tian J; Yao X
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
[TBL] [Abstract][Full Text] [Related]
13. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment.
Nakai Y; Nishimura K; Nakayama M; Uemura M; Takayama H; Nonomura N; Tsujimura A;
Int J Clin Oncol; 2014 Feb; 19(1):165-72. PubMed ID: 23456140
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
16. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis.
Wu Y; Shao N; Shen ZX; Li Q; Wang Y; Li C; Ma G; Dong J; Lu XJ; Feng NH
Eur Rev Med Pharmacol Sci; 2014; 18(21):3291-6. PubMed ID: 25487941
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Bianco V; Ponchietti R; Barbanti G; Francini E
Clin Genitourin Cancer; 2015 Oct; 13(5):441-6. PubMed ID: 25920994
[TBL] [Abstract][Full Text] [Related]
19. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
